Votrient (pazopanib) is a prescription drug used to treat certain types of cancer. Votrient can cause side effects that range from mild to serious. Examples include diarrhea and high blood pressure.

Votrient (pazopanib) is a brand-name drug prescribed for certain types of advanced cancer in adults. Votrient comes as an oral tablet that’s typically taken once per day. Advanced cancer can refer to ...

On June 4, 2011, Glaxo had reported positive data from a phase III trial of Votrient at the American Society for Clinical Oncology (TATD). The PALETTE (PAzopanib ExpLorEd in SofT-Tissue Sarcoma) study ...

VOTRIENT (pazopanib) 200mg, 400mg tablets by GlaxoSmithKline The FDA has approved Votrient (pazopanib tablets, from GlaxoSmithKline), an angiogenesis inhibitor, for the treatment of advanced renal ...

NICE has recommended that Votrient (pazopanib) be considered as a first-line treatment option for patients with advanced renal cell carcinoma who have not previously received cytokine therapy, ruling ...

PHILADELPHIA, April 26, 2012 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has approved Votrient ® (pazopanib) for the treatment ...

GlaxoSmithKline (GSK) has abandoned its bid to extend Votrient’s (pazopanib) in advanced ovarian cancer, withdrawing an EU licence application and abandoning development in any other countries. The ...

Oct. 21 -- TUESDAY, Oct. 20 (HealthDay News) -- Votrient (pazopanib) has been approved to treat advanced renal cell carcinoma, a form of kidney cancer in which cancerous cells invade the lining of ...

In Jun 2013, the company had announced encouraging data from a phase III trial (n = 940) on Votrient. The randomized, double-blind, placebo-controlled trial evaluated the use of Votrient in women ...

On June 4, 2011, Glaxo had reported positive data from a phase III trial of Votrient at the American Society for Clinical Oncology (TATD). The PALETTE (PAzopanib ExpLorEd in SofT-Tissue Sarcoma) study ...